Skip Navigation

Cardiovascular Research 2004 63(3):500-509; doi:10.1016/j.cardiores.2004.03.015
© 2004 by European Society of Cardiology
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Hardt, S. E
Right arrow Articles by Sadoshima, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hardt, S. E
Right arrow Articles by Sadoshima, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2004, European Society of Cardiology

Negative regulators of cardiac hypertrophy

Stefan E Hardta,b and Junichi Sadoshima*,a

aDepartment of Cell Biology and Molecular Medicine, UMDNJ, Cardiovascular Research Institute, 185 South Orange Avenue, MSB G-609, Newark, NJ 07103-2714, USA
bDepartment of Cardiology, University of Heidelberg, Heidelberg, Germany

* Corresponding author. Tel.: +1-973-972-8619; fax: +1-973-972-8919. Email address: sadoshju{at}umdnj.edu

Throughout the past decade, much effort has been spent on deciphering the signaling pathways positively mediating cardiac hypertrophy. Recently, several endogenous molecules in the heart have been shown to negatively regulate cardiac hypertrophy. One group of these molecules is constitutively active at baseline, while molecules belonging to the second group serve as negative feedback regulators, which are activated in response to pathologic insults. Studies upon the negative regulators of cardiac hypertrophy may allow us to develop novel strategies to treat heart failure by mimicking the naturally preferred mechanisms to maintain homeostasis. In addition, the search for molecular targets of these negative regulators may allow us to identify novel positive mediators of hypertrophy. The aim of this article is to provide a brief overview of these newly identified negative regulators of cardiac hypertrophy.

KEYWORDS Hypertrophy; Signal transduction; Negative regulation

Time for primary review 21 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Circ. Res.Home page
A. M. Samarel
PICOT: A Multidomain Scaffolding Inhibitor of Hypertrophic Signal Transduction
Circ. Res., March 28, 2008; 102(6): 625 - 627.
[Full Text] [PDF]

Home page
 Circ. Res.Home page
D. Jeong, J. M. Kim, H. Cha, J. G. Oh, J. Park, S.-H. Yun, E.-S. Ju, E.-S. Jeon, R. J. Hajjar, and W. J. Park
PICOT Attenuates Cardiac Hypertrophy by Disrupting Calcineurin-NFAT Signaling
Circ. Res., March 28, 2008; 102(6): 711 - 719.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. A. Hill and E. N. Olson
Cardiac Plasticity
N. Engl. J. Med., March 27, 2008; 358(13): 1370 - 1380.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.